PHARMACOLOGY Correction for "Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer," by Sandra Blasco-Benito, Estefanía Moreno, Marta Seijo-Vila, Isabel Tundidor, Clara Andradas, María M. Caffarel, Miriam Caro-Villalobos, Leyre Urigüen, Rebeca Diez-Alarcia, Gema Moreno-Bueno, Lucía Hernández, Luis Manso, Patricia Homar-Ruano, Peter J. McCormick, Lucka Bibic, Cristina Bernadó-Morales, Joaquín Arribas, Meritxell Canals, Vicent Casadó, Enric I. Canela, Manuel Guzmán, Eduardo Pérez-Gómez, and Cristina Sánchez, which was first published February 7, 2019; 10.1073/pnas.1815034116 (Proc Natl Acad Sci USA 116:3863-3872). The authors note that, due to a printer's error, the affiliation for Lucka Bibic appeared incorrectly. It should instead appear as School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom. The corrected author and affiliation lines appear below. The online version has been corrected.
CITATION STYLE
Blasco-Benito, S., Moreno, E., Seijo-Vila, M., Tundidor, I., Andradas, C., Caffarel, M. M., … Sánchez, C. (2019). Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116). Proceedings of the National Academy of Sciences of the United States of America. National Academy of Sciences. https://doi.org/10.1073/pnas.1903209116
Mendeley helps you to discover research relevant for your work.